ALISO VIEJO, Calif.--(BUSINESS WIRE)--Dec 28, 2022--

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 41 st Annual J.P Morgan Healthcare Conference on Tuesday, January 10, 2023, at 5:15 p.m. PT in San Francisco, CA.

A live and archived webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.

About Glaukos

Glaukos ( www.glaukos.com ) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and continues to develop a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases.

View source version on businesswire.com:https://www.businesswire.com/news/home/20221228005284/en/

CONTACT: Chris Lewis

Vice President, Investor Relations & Corporate Affairs

(949) 481-0510

clewis@glaukos.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: PHARMACEUTICAL OPTICAL HEALTH MEDICAL DEVICES

SOURCE: Glaukos Corporation

Copyright Business Wire 2022.

PUB: 12/28/2022 04:15 PM/DISC: 12/28/2022 04:16 PM

http://www.businesswire.com/news/home/20221228005284/en